Reference : Allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning...
Scientific journals : Letter to the editor
Life sciences : Microbiology
Life sciences : Genetics & genetic processes
Life sciences : Biotechnology
Allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning as treatment for hematologic malignancies and inherited blood disorders
Baron, Frédéric mailto [Université de Liège - ULiège > Département des sciences cliniques > Hématologie]
Storb, R. [> > > >]
Molecular Therapy
Academic Press Inc Elsevier Science
Yes (verified by ORBi)
San Diego
[en] hematopoietic cell transplantation ; nonmyeloablative conditioning ; mixed chimerism ; graft-versus-tumor effects ; graft-versus-host disease
[en] Allogeneic hematopoietic cell transplantation (HCT) after myeloablative conditioning regimens has been an effective treatment for many patients with hematologic malignancies or inherited blood disorders. Unfortunately, such regimens have been associated with significant toxicity, limiting their use to otherwise healthy, relatively young patients. In an attempt to extend treatment by allogeneic HCT to older patients and those with comorbid conditions, several groups of investigators have developed reduced-intensity or truly nonmyeloablative conditioning regimens, lacking such toxicity. Analogous to conventional regimens, reduced-intensity regimens both eliminated host-versus-graft (rejection) reactions and produced major anti-tumor effects. In contrast, nonmyeloablative regimens have relied on optimizing both pre-and posttransplant immunosuppression to overcome host-versus-g raft reactions, while anti-tumor responses have depended mainly on immune-mediated graft-versus-tumor effects. In this review, we define reduced-intensity and truly nonmyeloablative regimens, describe the preclinical development and clinical application of a very low intensity nonmyeloablative regimen, and review results with reduced-intensity regimens in patients with hematologic malignancies or inherited blood disorders.

File(s) associated to this reference

Fulltext file(s):

Restricted access
BaronMolTher06.pdfPublisher postprint314.64 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.